These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

438 related items for PubMed ID: 31550660

  • 21. Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidine derivatives containing 1,8-naphthyridine-4-one fragment.
    Zhang J, Chen P, Duan Y, Xiong H, Li H, Zeng Y, Liang G, Tang Q, Wu D.
    Eur J Med Chem; 2021 Apr 05; 215():113273. PubMed ID: 33601310
    [Abstract] [Full Text] [Related]

  • 22. Novel benzotriazole N-acylarylhydrazone hybrids: Design, synthesis, anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis and FAK inhibition.
    Kassab AE, Hassan RA.
    Bioorg Chem; 2018 Oct 05; 80():531-544. PubMed ID: 30014921
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Design, synthesis, biological evaluation and molecular modeling of novel 1H-pyrrolo[2,3-b]pyridine derivatives as potential anti-tumor agents.
    Wang R, Chen Y, Yang B, Yu S, Zhao X, Zhang C, Hao C, Zhao D, Cheng M.
    Bioorg Chem; 2020 Jan 05; 94():103474. PubMed ID: 31859010
    [Abstract] [Full Text] [Related]

  • 25. Phosphamide-containing diphenylpyrimidine analogues (PA-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with enhanced activity against pancreatic cancer cell lines.
    Liu H, Wu B, Ge Y, Huang J, Song S, Wang C, Yao J, Liu K, Li Y, Li Y, Ma X.
    Bioorg Med Chem; 2017 Dec 15; 25(24):6313-6321. PubMed ID: 29102081
    [Abstract] [Full Text] [Related]

  • 26. Tyrosine kinase inhibition effects of novel Pyrazolo[1,5-a]pyrimidines and Pyrido[2,3-d]pyrimidines ligand: Synthesis, biological screening and molecular modeling studies.
    El Sayed MT, Hussein HAR, Elebiary NM, Hassan GS, Elmessery SM, Elsheakh AR, Nayel M, Abdel-Aziz HA.
    Bioorg Chem; 2018 Aug 15; 78():312-323. PubMed ID: 29625271
    [Abstract] [Full Text] [Related]

  • 27. Discovery of 2,4-diarylaminopyrimidine derivatives bearing sulfonamide moiety as novel FAK inhibitors.
    Li R, Gong L, Sun J, Liang Z, He J, Huang J, Ning X, Song H, Li R, Zhang Q, Lin Z, Yin Y.
    Bioorg Chem; 2024 Mar 15; 144():107134. PubMed ID: 38237389
    [Abstract] [Full Text] [Related]

  • 28. Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity.
    Hossam M, Lasheen DS, Ismail NSM, Esmat A, Mansour AM, Singab ANB, Abouzid KAM.
    Eur J Med Chem; 2018 Jan 20; 144():330-348. PubMed ID: 29275232
    [Abstract] [Full Text] [Related]

  • 29. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
    Bakr RB, Mehany ABM, Abdellatif KRA.
    Anticancer Agents Med Chem; 2017 Jan 20; 17(10):1389-1400. PubMed ID: 28270084
    [Abstract] [Full Text] [Related]

  • 30. Discovery of novel pyrrolopyrimidine/pyrazolopyrimidine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors.
    Wang L, Liu X, Duan Y, Li X, Zhao B, Wang C, Xiao Z, Zheng P, Tang Q, Zhu W.
    Chem Biol Drug Des; 2018 Jul 20; 92(1):1301-1314. PubMed ID: 29575727
    [Abstract] [Full Text] [Related]

  • 31. Design, synthesis and biological evaluation of ring-fused pyrazoloamino pyridine/pyrimidine derivatives as potential FAK inhibitors.
    Xie H, Lin X, Zhang Y, Tan F, Chi B, Peng Z, Dong W, An D.
    Bioorg Med Chem Lett; 2020 Nov 01; 30(21):127459. PubMed ID: 32784087
    [Abstract] [Full Text] [Related]

  • 32. Design, synthesis and biological evaluation of novel 2,4-bismorpholinothieno[3,2-d]pyrimidine and 2-morpholinothieno[3,2-d]pyrimidinone derivatives as potent antitumor agents.
    Ye T, Han Y, Wang R, Yan P, Chen S, Hou Y, Zhao Y.
    Bioorg Chem; 2020 Jun 01; 99():103796. PubMed ID: 32283346
    [Abstract] [Full Text] [Related]

  • 33. Synthesis of novel 1,2,4-triazine scaffold as FAK inhibitors with antitumor activity.
    Dao P, Lietha D, Etheve-Quelquejeu M, Garbay C, Chen H.
    Bioorg Med Chem Lett; 2017 Apr 15; 27(8):1727-1730. PubMed ID: 28284808
    [Abstract] [Full Text] [Related]

  • 34. Design, synthesis and biological evaluation of thieno[3,2-d]pyrimidine derivatives containing aroyl hydrazone or aryl hydrazide moieties for PI3K and mTOR dual inhibition.
    Han Y, Tian Y, Wang R, Fu S, Jiang J, Dong J, Qin M, Hou Y, Zhao Y.
    Bioorg Chem; 2020 Nov 15; 104():104197. PubMed ID: 32927132
    [Abstract] [Full Text] [Related]

  • 35. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA, Sakr H, Ayyad RRA, El-Adl K, Ali MM, Khedr F.
    Anticancer Agents Med Chem; 2018 Nov 15; 18(8):1184-1196. PubMed ID: 29651967
    [Abstract] [Full Text] [Related]

  • 36. The synthesis and bioactivity of pyrrolo[2,3-d]pyrimidine derivatives as tyrosine kinase inhibitors for NSCLC cells with EGFR mutations.
    Xia Z, Huang R, Zhou X, Chai Y, Chen H, Ma L, Yu Q, Li Y, Li W, He Y.
    Eur J Med Chem; 2021 Nov 15; 224():113711. PubMed ID: 34315040
    [Abstract] [Full Text] [Related]

  • 37. Design, synthesis, anticancer evaluation, molecular docking and cell cycle analysis of 3-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine derivatives as potent histone lysine demethylases (KDM) inhibitors and apoptosis inducers.
    Metwally NH, Mohamed MS, Ragb EA.
    Bioorg Chem; 2019 Jul 15; 88():102929. PubMed ID: 31015179
    [Abstract] [Full Text] [Related]

  • 38. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
    Hou J, Wan S, Wang G, Zhang T, Li Z, Tian Y, Yu Y, Wu X, Zhang J.
    Eur J Med Chem; 2016 Aug 08; 118():276-89. PubMed ID: 27132165
    [Abstract] [Full Text] [Related]

  • 39. Synthesis, biological evaluation, and molecular dynamics (MD) simulation studies of three novel F-18 labeled and focal adhesion kinase (FAK) targeted 5-bromo pyrimidines as radiotracers for tumor.
    Fang Y, Wang D, Xu X, Liu J, Wu A, Li X, Xue Q, Wang H, Wang H, Zhang H.
    Eur J Med Chem; 2017 Feb 15; 127():493-508. PubMed ID: 28109944
    [Abstract] [Full Text] [Related]

  • 40. Structure-based modification of carbonyl-diphenylpyrimidines (Car-DPPYs) as a novel focal adhesion kinase (FAK) inhibitor against various stubborn cancer cells.
    Wang L, Ai M, Yu J, Jin L, Wang C, Liu Z, Shu X, Tang Z, Liu K, Luo H, Guan W, Sun X, Ma X.
    Eur J Med Chem; 2019 Jun 15; 172():154-162. PubMed ID: 30978560
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.